Patients with a sustained inflammatory response, as defined by elevated levels of SAA1, SAA2 and CRP, are classified as NSCLC “Poor” and do not respond to single-agent immunotherapy as well as patients without elevated SAA1, SAA2 and CRP (NSCLC “Good”) [23,24]. This evidence concerns the gene SAA2 and non-small cell lung carcinoma.